Table 1 Potency and selectivity of synthetic ProTX-II and JNJ63955918.

From: Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor

Peptide

 

hNav1.7

hNav1.1

hNav1.2

hNav1.3

hNav1.4

hNav1.5

hNav1.6

ProTX-II QP

pIC50

9.1 ± 0.06

7.8 ± 0.08

7.1 ± 0.07

7.6 ± 0.09

7.1 ± 0.07

6.4 ± 0.07

7.5 ± 0.04

 

Fitted Emax (%)

88.8 ± 3.1

100

100

100

100

100

100

 

Fold Nav1.7 Selectivity

—

19.8

99.3

31.4

99.3

497.6

39.5

JNJ63955918 QP

pIC50

8.0 ± 0.09

5.2 ± 0.13

6.1 ± 0.38

nd

4.8 ± 0.13

<5.5

5.6 ± 0.11

 

Fitted Emax (%)

79.1 ± 3.4

100

27.6 ± 7.3

nd

100

 

100

 

Fold Nav1.7 Selectivity

—

631

79.4

nd

1584.9

>316.2

251.2

JNJ63955918 MPC

pIC50

8.0 ± 0.08

5.0 ± 0.06

5.8 ± 0.46

nd

5.3 ± 0.11

<5.0

6.0 ± 0.04

 

Fitted Emax (%)

94.8 ± 3.3

100

50.0 ± 18.5

nd

100

 

100

 

Fold Nav1.7 Selectivity

—

1000

158.5

nd

501.2

>1000

100

  1. (IC50 is defined as the concentration to produce inhibition equivalent to 50% of the fitted Emax).
  2. QP = IC50 determined by automated electrophysiology using QPatch.
  3. MPC = IC50 determined by conventional manual patch-clamp electrophysiology.
  4. Fold Nav1.7 selectivity = 10^(Nav1.7 pIC50 − Nav1.x pIC50).